Cytokinetics, Incorporated
(NASDAQ : CYTK)

( )
CYTK PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.12%200.811.2%$402.10m
GILDGilead Sciences, Inc.
0.01%72.790.9%$394.52m
CELGCelgene Corporation
0.18%87.361.2%$339.76m
BIIBBiogen Inc.
-1.26%334.401.2%$273.97m
ILMNIllumina, Inc.
-1.67%347.223.5%$252.24m
REGNRegeneron Pharmaceuticals, Inc.
-1.45%386.492.6%$210.24m
EXASExact Sciences Corporation
0.00%73.3325.3%$198.68m
VRTXVertex Pharmaceuticals Incorporated
-1.79%175.801.9%$159.87m
SRPTSarepta Therapeutics, Inc.
-0.27%152.3516.4%$124.87m
AAgilent Technologies, Inc.
0.33%69.081.5%$121.49m
ALXNAlexion Pharmaceuticals, Inc.
-0.33%117.812.0%$107.50m
ALNYAlnylam Pharmaceuticals, Inc
-3.90%93.359.7%$95.81m
NKTRNektar Therapeutics
-1.48%57.455.6%$94.55m
BMRNBioMarin Pharmaceutical Inc.
-1.27%98.154.4%$90.68m
INCYIncyte Corporation
-1.57%67.022.5%$87.71m

Company Profile

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.